<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520451</url>
  </required_header>
  <id_info>
    <org_study_id>ACT17125</org_study_id>
    <secondary_id>PRN1008-017</secondary_id>
    <nct_id>NCT04520451</nct_id>
  </id_info>
  <brief_title>Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients</brief_title>
  <official_title>An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patients With IgG4-Related Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Principia Biopharma, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRN1008-017 is a Phase 2a, multi-center, open-label, two-arm study of approximately 25&#xD;
      patients with active IgG4-related disease (IgG4-RD). The two arms include (1) Experimental:&#xD;
      PRN1008 with glucocorticoids and (2) Active Comparator: glucocorticoids only.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 25 patients with active IgG4-RD will be enrolled in two arms of the trial: (1)&#xD;
      Experimental: PRN1008 with glucocorticoids and (2) Active Comparator: glucocorticoids only.&#xD;
&#xD;
      Patients who meet all the inclusion criteria and none of the exclusion criteria after&#xD;
      completion of the 4-week Screening Period will be randomized in a 3:1 ratio to the PRN1008&#xD;
      with glucocorticoids arm or the glucocorticoids only arm. The Main Treatment Period is 12&#xD;
      weeks, and patients may then be eligible to enroll in a Treatment Extension Period of 40&#xD;
      weeks, followed by a 4-week Safety Follow-up Period.&#xD;
&#xD;
      In the Active Comparator arm, a patient will be considered a treatment failure if the&#xD;
      glucocorticoid therapy cannot be discontinued by 12 weeks and will be eligible to cross-over&#xD;
      to the Experimental arm, and receive 12 weeks of PRN1008 in the Main Treatment Period,&#xD;
      followed by the potential to enroll in the Treatment Extension Period for an additional 40&#xD;
      weeks, followed by a 4-week Safety Follow-up Period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2020</start_date>
  <completion_date type="Anticipated">December 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients who achieve complete remission at Week 12 with no glucocorticoid use at Week 4 for the Experimental Arm and Week 12 for the Active Comparator Arm.</measure>
    <time_frame>Week 4 to Week 12</time_frame>
    <description>Complete remission defined as an IgG4-RD Responder Index of zero</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum IgG4 concentrations</measure>
    <time_frame>Week 0 to Week 56</time_frame>
    <description>Level and change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG4-RD Responder Index</measure>
    <time_frame>Week 0 to Week 56</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>IgG4-Related Disease</condition>
  <arm_group>
    <arm_group_label>PRN1008 plus glucocorticoids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRN1008 tablets, 400 mg twice daily from Week 0 to Week 12 plus glucocorticoids (20 to 40 mg/day prednisone equivalent tapered to 0 mg/day within 2 weeks on study)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucocorticoids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucocorticoids (20 to 40 mg/day prednisone equivalent tapered to 0 mg/day within 12 weeks on study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rilzabrutinib</intervention_name>
    <description>oral small molecule BTK inhibitor</description>
    <arm_group_label>PRN1008 plus glucocorticoids</arm_group_label>
    <other_name>PRN1008</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoids</intervention_name>
    <description>corticosteroid, anti-inflammatory, or immunosuppressant</description>
    <arm_group_label>Glucocorticoids</arm_group_label>
    <arm_group_label>PRN1008 plus glucocorticoids</arm_group_label>
    <other_name>prednisone</other_name>
    <other_name>prednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Be male or female with age â‰¥ 18 years.&#xD;
&#xD;
          2. Have a clinical diagnosis of IgG4-RD&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Currently or within 6 months of screening taking rituximab, other B-cell depleting&#xD;
             agents, or alkylating agents unless B cell concentrations have been demonstrated by&#xD;
             flow cytometry to return to normal values (defined as 5 cells per cubic mm).&#xD;
&#xD;
          2. History of solid organ transplant&#xD;
&#xD;
          3. Positive at Screening for HIV, hepatitis B, hepatitis C, or TB&#xD;
&#xD;
          4. Female patients who are pregnant or nursing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 84019</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 84016</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 84018</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 84030</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 12403</name>
      <address>
        <city>Vancouver</city>
        <zip>V6K 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wallace ZS, Zhang Y, Perugino CA, Naden R, Choi HK, Stone JH; ACR/EULAR IgG4-RD Classification Criteria Committee. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis. 2019 Mar;78(3):406-412. doi: 10.1136/annrheumdis-2018-214603. Epub 2019 Jan 5.</citation>
    <PMID>30612117</PMID>
  </reference>
  <verification_date>October 8, 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>+IgG4</keyword>
  <keyword>glucocorticoid</keyword>
  <keyword>IgG4-RD</keyword>
  <keyword>BTK</keyword>
  <keyword>Bruton's</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin G4-Related Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

